文献速递造血干细胞移植与细胞治疗

血清硫氧还蛋白可预测异基因造血干细胞移植后急性GVHD

Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft-versus-host disease.
PubMed 文献 · Br J Haematol · 2026-09-06

该研究纳入2022—2025年首次接受allo-HSCT的118例患者作为训练队列,并纳入2012—2015年首次移植且第0天前后血清冻存的47例患者作为验证队列,检测第0天血清硫氧还蛋白(TXN)水平。高TXN组II-IV级急性GVHD累积发生率数值较低但未达统计学显著,多因素分析显示高TXN组急性GVHD风险显著降低(HR 0.48,p=0.031),TXN联合临床因素可提升预测效能(p=0.0039)。

要点

  • 高TXN组急性GVHD风险显著降低(HR 0.48,p=0.031)
  • 100天II-IV级急性GVHD发生率:训练队列47.5% vs 59.2%(p=0.058)
  • TXN联合临床因素较单用临床因素提升急性GVHD预测效能(p=0.0039)

核心结论

  • 高TXN与急性GVHD风险降低显著相关,TXN可能有助于预测急性GVHD并构建预测模型。

研究设计与样本

  • 训练队列为2022—2025年首次接受allo-HSCT的118例患者,序贯采集第0天血清。
  • 验证队列为2012—2015年首次接受allo-HSCT的47例患者,第0天前后血清此前已冻存且可用。

主要发现

  • 训练队列高TXN组II-IV级急性GVHD的100天累积发生率为47.5% vs 59.2%,差异未达统计学显著(p=0.058)。
  • 验证队列结果相似:0% vs 35.8%(p=0.053)。
  • 多因素分析显示高TXN组与急性GVHD风险降低显著相关(HR 0.48,p=0.031)。
  • TXN联合临床因素较单用临床因素提升对急性GVHD的预测潜力(p=0.0039)。

关键数值与推荐

  • 训练队列100天II-IV级急性GVHD累积发生率:高TXN组47.5% vs 59.2%(p=0.058)。
  • 验证队列II-IV级急性GVHD发生率:0% vs 35.8%(p=0.053)。
  • 多因素分析:高TXN组急性GVHD的HR 0.48(p=0.031)。
  • TXN联合临床因素与单用临床因素预测急性GVHD比较:p=0.0039。

临床怎么用

  • 可在allo-HSCT第0天检测血清TXN,用于辅助评估急性GVHD风险。
  • 可将TXN与临床因素联合用于急性GVHD预测模型的构建。
  • TXN预测价值仍需结合多因素分析结果综合解读,单因素发生率差异未达显著。

局限性

  • 训练队列与验证队列样本量分别为118例和47例,验证队列为历史冻存血清。
  • 单因素比较中急性GVHD发生率差异未达统计学显著(p=0.058、p=0.053)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft-versus-host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo-HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo-HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high-TXN group showed a lower cumulative incidence of grade II-IV acute GVHD (100-day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance (p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high-TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone (p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tamaki M, Nakasone H, Takano K, et al. Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft-versus-host disease. Br J Haematol. 2026. PMID: 42702760. doi:10.1111/bjh.70739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。